ImmuCell (ICCC) Peer Comparison
$10.02
$0.23
(2.30%)
As on 01-Sep-2026 09:47EDT
Market cap
$90 Mln
Revenue (TTM)
$31 Mln
P/E Ratio
142
P/B Ratio
2.9
Div. Yield
0 %
Edit
| ImmuCell (ICCC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
90 | 16,765 | 16,261 | 13,492 | 11,994 |
Revenue ($ Mln) |
31 | 2,782 | 1,054 | 2,436 | 670 |
Net Profit ($ Mln) |
0.79 | 491.50 | 755.85 | 860.62 | -319.95 |
Net Margin (%) |
2.57 | 17.67 | 71.69 | 35.33 | -47.79 |
RoE (%) |
2.70 | 110.09 | -- | 42.98 | -71.14 |
Price to Earnings |
142.00 | 35.25 | 19.00 | 17.40 | -- |
Price-To-Book |
2.91 | 39.29 | 9.76 | 7.42 | 26.87 |
Income Statement ($ Mln)
| ImmuCell (ICCC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
30.68 | 2,782.29 | 1,054.37 | 2,435.92 | 669.50 |
|
Cost of Revenue
|
18.31 | 1,982.07 | 103.47 | 85.67 | 19.14 |
|
Gross Profit
|
11.45 | 760.62 | 588.53 | 2,236.43 | 829.45 |
|
Operating Expenses
|
8.50 | 216.81 | 841.45 | 1,378.74 | 895.93 |
|
Operating Profit (EBIT)
|
3.87 | 583.40 | 109.45 | 971.51 | -226.44 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
0.85 | 598.92 | 101.11 | 1,035.47 | -252.08 |
|
Provision for Tax
|
0.07 | 107.42 | -654.74 | 174.84 | 20.05 |
|
Profit after Tax (Net Income)
|
0.79 | 491.50 | 755.85 | 860.62 | -319.95 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | -47.83 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| ImmuCell (ICCC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
31.37 | 433.86 | 1,435.90 | 1,843.76 | 465.53 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | -47.83 |
|
Non-Current Liabilities
|
10.82 | 187.89 | 384.48 | 288.55 | 1,362.63 |
|
Current Liabilities
|
4.44 | 1,435.43 | 464.70 | 361.93 | 283.35 |
|
Total Liabilities
|
42.53 | 1,975.47 | 1,302.02 | 2,844.42 | 1,385.30 |
Assets ($ Mln)
| ImmuCell (ICCC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
25.55 | 1,006.90 | 895.24 | 1,243.41 | 440.60 |
|
Current Assets
|
21.08 | 1,050.29 | 1,389.84 | 1,250.82 | 1,671.41 |
|
Total Assets
|
42.53 | 1,975.47 | 1,302.02 | 2,844.42 | 1,385.30 |
|
Total Debt*
|
12.45 | 120.10 | 449.89 | 165.93 | 864.07 |
|
Net Current Assets
|
0.00 | -385.14 | 0.00 | 888.90 | 1,388.07 |
Cashflow ($ Mln)
| ImmuCell (ICCC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
2.48 | 713.22 | 51.77 | 884.27 | 179.55 |
|
Cash Flow from Investing Activities
|
-1.21 | -31.14 | -8.15 | 350.44 | -129.29 |
|
Cash from Financing Activities
|
-1.21 | -860.39 | 34.89 | -969.59 | 74.01 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| ImmuCell (ICCC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-2.51 | 53.56 | -30.01 | 32.82 | -0.17 |
|
ROE (%)
|
2.70 | 110.09 | 163.18 | 42.98 | -71.14 |
|
ROA (%)
|
1.32 | 15.64 | 26.53 | 29.32 | -16.12 |
|
EBIT Margin (%)
|
3.76 | 21.13 | 5.73 | 31.04 | -0.77 |
|
Net Margin (%)
|
2.57 | 17.67 | 71.69 | 35.33 | -47.79 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| ImmuCell (ICCC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
8.49 | 24.67 | 114.85 | 9.23 | 12.22 |
|
EBIT Growth (%)
|
-36.61 | 18.70 | 136.39 | -3.99 | 93.17 |
|
Net Profit Growth (%)
|
-55.31 | 17.50 | 378.76 | 42.89 | -115.58 |
|
EPS Growth (%)
|
-55.46 | 26.84 | 353.27 | 50.42 | -73.87 |
|
Book Value Growth (%)
|
3.24 | 164.02 | 816.12 | -0.70 | -13.57 |
Valuation Ratios
| ImmuCell (ICCC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-53.49 | 36.06 | -59.76 | 15.79 | -2,869.63 |
|
Price / Book Value
|
2.06 | 35.44 | -80.42 | 5.72 | 10.04 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
30.38 | 28.08 | -121.54 | 12.44 | 25.04 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| ImmuCell (ICCC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.00 | 0.00 | 0.00 | 1.77 |
|
Short term debt to equity ratio
|
0.05 | 0.00 | 0.05 | 0.00 | 0.09 |
|
Current Ratio
|
4.75 | 0.73 | 2.99 | 3.46 | 5.90 |
|
Quick Ratio
|
2.71 | 0.73 | 2.32 | 3.38 | 5.90 |
|
Interest Coverage
|
2.97 | -- | 1.62 | -- | -1.72 |
Operating Efficiency Ratios
| ImmuCell (ICCC) | Medpace Holdings (MEDP) | Ascendis Pharma A/S - ADR | Exelixis (EXEL) | Arrowhead Pharmaceuticals (ARWR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
9.44 | 15.88 | 21.25 | 13.74 | 1.28 |
|
Asset Turnover
|
0.52 | 0.89 | 0.37 | 0.83 | 0.34 |
|
Receivable days
|
47.77 | 50.42 | 85.52 | 43.48 | 1.50 |
|
Inventory Days
|
184.66 | -- | 1,056.70 | 96.17 | -- |
|
Payable days
|
19.62 | 6.26 | 331.01 | 147.97 | 221.81 |
|
Cash Conversion Cycle
|
212.81 | -- | 811.21 | -8.32 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
